Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: GREGIANIN
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Autorzy: Gregianin Lauro J., Brunetto Algemir L., Leone Luciane Di, Costa Teresa Dalla, Santos Pedro P., Schwartsmann Gilberto
Źródło: Med. Sci. Monitor 2002: 8 (9) s.PI70-PI77, il., tab., bibliogr. 31 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • onkologia
  • farmacja
  • pediatria
  • toksykologia

    Typ dokumentu:
  • tytuł obcojęzyczny
  • praca kliniczna

    Wskaźnik treści:
  • ludzie
  • dzieci 2-5 r.ż.
  • dzieci 6-12 r.ż.
  • dzieci 13-18 r.ż.

    Streszczenie angielskie: Background: The purpose of this phase I study was to evaluate the toxicity profile, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and plasma pharmacokinetics of oral etoposide, and to recommend a safe fractionated dose for phase II trials in pediatric patients with refractory solid tumors. Material/Methods: All patients had tumors no longer amenable to established forms of treatment. The initial dose of etoposide was 20 mg/mý TID for 14 days every 21 days (dose-level I). Etoposide plasma pharmacokinetics were studied on day 1 of treatment and determined by PHLC. Results: Seventeen children were enrolled, 13 of whom were included in the pharacokinetic study, for a total of 64 courses. nine patients were included at dose-level I; grade 2-3 leucopenia was observed in 5. The dose was then raised to 25 mg/mý (dose-level II) in another 8 patients; grade 3-4 leucopenia was observed in 4. This dose-level was therefore considered the MTD. The DLT was neutropenia. In patients at dose-level I and II the maximum plasma etoposide concentration was 2.97 and 8.59 ćg/ml, respectively. Drug levels 1 ćg/ml were maintained for about 6.3 hours following drug administration at both dose-levels. Partial response was observed in 1 patient and 4 patients showed stable disease. Conclusions: Prolonged oral etoposide was well tolerated by our patients. Considering the MTD, and fact that the patients included at dose-level I achieved an adequate ( 1 ćg/ml) plasma concentration of etoposide for a sufficient time, this dose level was recommended for phase II studies in pediatric malignancies...

    stosując format: